Inactivating Variants in ANGPTL4 and Risk of Coronary Artery Disease
Open accessThe DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Higher-than-normal levels of circulating triglycerides are a risk factor for ischemic cardiovascular disease. Activation of lipoprotein lipase, an enzyme that is inhibited by angiopoietin-like 4 (ANGPTL4), has been shown to reduce levels of circulating triglycerides. METHODS: We sequenced the exons of ANGPTL4 in samples obtain from 42,930 participants of predominantly European ancestry in the DiscovEHR human genetics study. We performed tests of association between lipid levels and the missense E40K variant (which has been associated with reduced plasma triglyceride levels) and other inactivating mutations. We then tested for associations between coronary artery disease and the E40K variant and other inactivating mutations in 10,552 participants with coronary artery disease and 29,223 controls. We also tested the effect of a human monoclonal antibody against ANGPTL4 on lipid levels in mice and monkeys. RESULTS: We identified 1661 heterozygotes and 17 homozygotes for the E40K variant and 75 participants who had 13 other monoallelic inactivating mutations in ANGPTL4. The levels of triglycerides were 13% lower and the levels of high-density lipoprotein (HDL) cholesterol were 7% higher among carriers of the E40K variant than among noncarriers. Carriers of the E40K variant were also significantly less likely than noncarriers to have coronary artery disease (odds ratio, 0.81; 95% confidence interval, 0.70 to 0.92; P=0.002). K40 homozygotes had markedly lower levels of triglycerides and higher levels of HDL cholesterol than did heterozygotes. Carriers of other inactivating mutations also had lower triglyceride levels and higher HDL cholesterol levels and were less likely to have coronary artery disease than were noncarriers. Monoclonal antibody inhibition of Angptl4 in mice and monkeys reduced triglyceride levels. CONCLUSIONS: Carriers of E40K and other inactivating mutations in ANGPTL4 had lower levels of triglycerides and a lower risk of coronary artery disease than did noncarriers. The inhibition of Angptl4 in mice and monkeys also resulted in corresponding reductions in these values. (Funded by Regeneron Pharmaceuticals.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Similarly, inactivating variants in ANGPTL4, a key inhibitor of LPL, have been shown to reduce levels of TGs, LDL-C, and HDL-C. Individuals with these variants exhibit lifelong reductions in circulating TGs and up to a 19% lower risk of CAD [26].”
From Targeting Triglycerides in Cardiovascular Disease Prevention: Evidence, Mechanisms, and Emerging Therapies (2026) · cites this paper as [26]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“rare loss-of-function mutations in the lipoprotein lipase (LPL) gene are associated with higher plasma triglyceride levels and a higher risk of cardiovascular disease”
From Association of Triglyceride-Lowering LPL Variants and LDL-C–Lowering LDLR Variants With Risk of Coronary Heart Disease (2019) · cites this paper as [12]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“while rare, loss-of-function mutations in the APOC3, ANGPTL3, and ANGPTL4 genes, which encode for natural inhibitors of LPL, are associated with lower triglyceride levels and a corresponding lower risk of cardiovascular disease.[9][10][11][12][13]”
From Association of Triglyceride-Lowering LPL Variants and LDL-C–Lowering LDLR Variants With Risk of Coronary Heart Disease (2019) · cites this paper as [12]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Like mice, humans deficient in ANGPTL3, ANGPTL4, or ANGPTL8 have lower plasma triglycerides (56–58, 163–166).”
From Regulation of lipoprotein metabolism by ANGPTL3, ANGPTL4, and ANGPTL8 (2021) · cites this paper as [56]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Mendelian randomization studies focused on variants in the genes encoding apoAV, apoCIII, lipoprotein lipase (LpL) and the angiopoietin-like proteins 3, 4, and 8 (ANGPTL3, ANGPTL4, and ANGPTL8) have been highly informative.29–35”
10 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Genome Analysis Toolkit: A MapReduce framework for analyzing next-generation DNA sequencing data
McKenna, A., Hanna, M., Banks, E., Sivachenko, A., Cibulskis, K., Kernytsky, A., Garimella, K., Altshuler, D., Gabriel, S., Daly, M., et al. (2010) · Genome Research · doi:10.1101/gr.107524.110 · Cited by 27,895
Cingolani, P., Platts, A., Wang, L. L., Coon, M., Nguyen, T., Wang, L., Land, S. J., Lu, X., & Ruden, D. M. (2012) · Fly · doi:10.4161/fly.19695 · Cited by 11,816
GCTA: a tool for genome-wide complex trait analysis
Yang, J., Lee, S. H., Goddard, M. E., & Visscher, P. M. (2011) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2010.11.011 · Cited by 8,279
Van der Auwera, G. A., Carneiro, M. O., Hartl, C., Poplin, R., del Angel, G., Levy‐Moonshine, A., Jordan, T., Shakir, K., Roazen, D., Thibault, J., et al. (2013) · Current Protocols in Bioinformatics · doi:10.1002/0471250953.bi1110s43 · Cited by 6,687
A solution to the problem of separation in logistic regression
Heinze, G., & Schemper, M. (2002) · Statistics in Medicine · doi:10.1002/sim.1047 · Cited by 2,711
Triglycerides and Cardiovascular Disease: A Scientific Statement From the American Heart Association
Miller, M., Stone, N. J., Ballantyne, C., Bittner, V., Criqui, M. H., Ginsberg, H. N., Goldberg, A. C., Howard, W. J., Jacobson, M. S., Kris-Etherton, P. M., et al. (2011) · Circulation · doi:10.1161/cir.0b013e3182160726 · Cited by 1,871
Li, B., & Leal, S. M. (2008) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2008.06.024 · Cited by 1,527
Triglycerides and cardiovascular disease
Nordestgaard, B. G., & Varbo, A. (2014) · The Lancet · doi:10.1016/s0140-6736(14)61177-6 · Cited by 1,419
Sarwar, N., Danesh, J., Eiriksdottir, G., Sigurdsson, G., Wareham, N., Bingham, S., Boekholdt, S. M., Khaw, K.-T., & Gudnason, V. (2007) · Circulation · doi:10.1161/circulationaha.106.637793 · Cited by 1,408
Research works printed but not linked: 2
- Van der Auwera GA, 2013, Curr Protoc Bioinformatics, 11, 11.10.1
- Romeo S, 2009, J Clin Invest, 119, 70
Cited by
Items 301–400 of 497
Borén, J., Packard, C. J., Nordestgaard, B. G., & Catapano, A. L. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf214 · Cited by 12
Predicting Thoracic Aortic Dissection in a Diverse Biobank Using a Polygenic Risk Score
DePaolo, J. S., Zamirpour, S., Abramowitz, S. A., Biagetti, G. M., Judy, R., Beeche, C., Duda, J., Gee, J. C., Witschey, W. R. T., Chirinos, J. A., et al. (2025) · JACC Advances · doi:10.1016/j.jacadv.2025.101743 · Cited by 15
Comparison of angiopoietin-like protein 3 and 4 reveals structural and mechanistic similarities
Gunn, K. H., Gutgsell, A. R., Xu, Y., Johnson, C. V., Liu, J., & Neher, S. B. (2021) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2021.100312 · Cited by 12
“Similarly, individuals with inactivating mutations in ANGPTL4 have lower triglycerides and a lower incidence of CAD than noncarriers (15, 16).”
BackgroundRemnant cholesterol, vascular risk, and prevention of atherosclerosis
Pintó, X., Fanlo‐Maresma, M., Esteve-Luque, V., & Millán, J. (2023) · Clínica e Investigación en Arteriosclerosis (English Edition) · doi:10.1016/j.artere.2023.07.005 · Cited by 18
ANGPTL4-the Link Binding Lipid Metabolism and Inflammation
Zhang, Y., Liang, J., Li, Z., Zuo, Y., & Dai, L. (2024) · Current Medicinal Chemistry · doi:10.2174/0109298673320024240829070906 · Cited by 12
Maidman, S. D., Hegele, R. A., & Rosenson, R. S. (2024) · Current Atherosclerosis Reports · doi:10.1007/s11883-024-01258-8 · Cited by 14
“Similar to ANGPTL3, Angiopoietin-like 4 (ANGPTL4) inhibits LPL, and LOF variants of ANGPTL4 are associated with both lower plasma TG levels and a reduced risk of ASCVD (odds ratio of 0.81) [63].”
InfluentialCircadian Angiopoietin-Like-4 as a Novel Therapy in Cardiovascular Disease
Shuff, S. R., Oyama, Y., Walker, L. A., & Eckle, T. D. L. G. (2021) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2021.04.007 · Cited by 14
Koohi, F., Khalili, D., Soori, H., Nazemipour, M., & Mansournia, M. A. (2022) · Global Epidemiology · doi:10.1016/j.gloepi.2022.100075 · Cited by 11
Chip-DSF: A rapid screening strategy for drug protein targets
Cui, Z., Chen, P., Li, C., Deng, S., & Yang, H. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106346 · Cited by 12
Liu, C., Gaudet, D., & Miller, Y. I. (2017) · PLoS ONE · doi:10.1371/journal.pone.0169939 · Cited by 11
Adipocyte-specific tribbles pseudokinase 1 regulates plasma adiponectin and plasma lipids in mice
Ha, E. E., Quartuccia, G. I., Ling, R., Xue, C., Karikari, R. A., Hernández‐Ono, A., Hu, K. Y., Matias, C. V., Imam, R., Cui, J. G., et al. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2021.101412 · Cited by 11
Genética de la cardiopatía isquémica: del conocimiento actual a las implicaciones clínicas
Elosúa, R., & Sayols-Baixeras, S. (2017) · Revista Española de Cardiología · doi:10.1016/j.recesp.2017.02.033 · Cited by 12
Profiling copy number variation and disease associations from 50,726 DiscovEHR Study exomesPreprint
Maxwell, E. K., Packer, J. S., O’Dushlaine, C. T., McCarthy, S., Hare-Harris, A. E., Staples, J. C., Gonzaga-Jauregui, C. G., Fetterolf, S. N., Faucett, W. A., Leader, J. B., et al. (2017) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/119461 · Cited by 12
Self-citationIdentifying novel drug targets for calcific aortic valve disease through Mendelian randomization
Xu, D., Lu, J., Yang, Y., Hu, W., Chen, J., Xue, J., Yang, S., Cao, N., Hu, H., Qian, N., et al. (2025) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2025.119110 · Cited by 10
Gugliucci, A. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13175229 · Cited by 11
“Additional roles of ANGPTL4 in the integrity of the intestinal barrier and interaction with microbiota are under intense scrutiny [49,51–54].”
BackgroundKelly, M. S., Beavers, C. J., Bucheit, J. D., Sisson, E. M., & Dixon, D. L. (2017) · Journal of clinical lipidology · doi:10.1016/j.jacl.2017.05.014 · Cited by 11
Genetics of early-onset coronary artery disease: from discovery to clinical translation
Lali, R., Cui, E., Ansarikaleibari, A., Pigeyre, M., & Paré, G. (2019) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000676 · Cited by 11
“Lossof-function mutations in APOA5, which codes for an LPL activator, significantly increased CAD risk, whereas loss-of-function mutations in APOC3, ANGPTL3 and ANGPTL4, which encode LPL inhibitors, were associated with decreased CAD risk [16,19,20].”
BackgroundAngiopoietin‐like protein 4 and clinical outcomes in ischemic stroke patients
Zheng, X., Shen, S., Wang, A., Zhu, Z., Peng, Y., Peng, H. Y., Zhong, C., Guo, D., Xu, T., Chen, J., et al. (2021) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.51319 · Cited by 11
“Some studies had found that ANGPTL-4 loss-of-function mutations were substantially associated with lower triglyceride levels, and a lower risk of coronary artery disease and ischemic stroke.(10,11,19) ANGPTL-4 might be involved in lipid metabolisms.”
BackgroundRole of Genetics in Preventive Cardiology: Focused on Dyslipidemia
Lee, S. (2021) · Korean Circulation Journal · doi:10.4070/kcj.2021.0239 · Cited by 10
Excipient of paclitaxel induces metabolic dysregulation and unfolded protein response
Dai, Q., Liu, X., He, T., Yang, C., Jiang, J., Fang, Y., Fu, Z., Yuan, Y., Bai, S., Qiu, T., et al. (2021) · iScience · doi:10.1016/j.isci.2021.103170 · Cited by 10
“…models have collectively established the central role of ANGPTL4 in the regulation of TG levels and cardiovascular diseases (Aryal et al., 2019; Dewey et al., 2016; Myocardial Infarction et al., 2016; Gusarova et al., 2018). iScience 24, 103170, October 22, 2021 5 We investigated the mechanism…”
BackgroundInfluentialANGPTL4, a multifaceted protein at the cross-talk between metabolism and cardiovascular disorders
Bouleti, C., Monnot, C., & Germain, S. (2018) · International Journal of Cardiology · doi:10.1016/j.ijcard.2017.10.123 · Cited by 10
Novel GPIHBP1-independent pathway for clearance of plasma TGs in Angptl4−/−Gpihbp1−/− mice
Cushing, E. M., Sylvers, K. L., Chi, X., Shetty, S. K., & Davies, B. J. (2018) · Journal of Lipid Research · doi:10.1194/jlr.m084749 · Cited by 10
“Preclinical studies suggest that targeting ANGPTL4 can lower plasma TGs in primates (14), and humans with homozygous deficiency in ANGPTL4 appear to be protected from cardiovascular disease (13, 14).”
BackgroundChen, Y., Johnson, S. M., Burr, S. D., Povero, D., Anderson, A. M., McMahon, C. E., & Liu, J. (2025) · Journal of Clinical Investigation · doi:10.1172/jci181754 · Cited by 9
“These findings bolster the concept that neutralization of ANGPTL4 has the potential to prevent both hypertriglyceridemia and atherogenesis (23, 24).”
Phenome-wide Mendelian randomization study of plasma triglyceride levels and 2600 disease traits
Park, J. K., Bafna, S., Forrest, I. S., Duffy, Á., Márquez‐Luna, C., Petrazzini, B. O., Vy, H. M. T., Jordan, D. M., Verbanck, M., Narula, J., et al. (2023) · eLife · doi:10.7554/elife.80560 · Cited by 10
“…targets have now been validated, including angiopoietin-like 3 (ANGPTL3) ( Graham et al., 2017 ; Dewey et al., 2017 ; Musunuru et al., 2010 ; Gaudet et al., 2017 ), angiopoietin-like 4 (ANGPTL4) ( Dewey et al., 2016 ), and apolipoprotein C-III (APOC3) ( Gaudet et al., 2015 ; Crosby et al., 2014 ).”
Alnassar, N., Hillman, C., Fontana, B. D., Robson, S. C., Norton, W., & Parker, M. O. (2023) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2023.08.004 · Cited by 9
Relaxin suppresses atrial fibrillation, reverses fibrosis and reduces inflammation in aged hearts
Romero, G., Martin, B., Gabris, B., & Salama, G. (2024) · Biochemical Pharmacology · doi:10.1016/j.bcp.2024.116407 · Cited by 9
Pedro‐Botet, J., Ascaso, J. F., Blasco, M., Brea, Á., Rodríguez, Á. D., Hernández‐Mijares, A., Pintó, X., & Millán, J. (2020) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2019.12.003 · Cited by 19
Poststatin era in atherosclerosis management: lessons from epidemiologic and genetic studies
Yvan‐Charvet, L., & Cariou, B. (2018) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000505 · Cited by 10
Khounphinith, E., Yin, R., Cao, X., Huang, F., Wu, J., & Li, H. (2019) · International Journal of Medical Sciences · doi:10.7150/ijms.31729 · Cited by 10
Liu, S., Wang, X., Yu, S., Yan, M., Peng, Y., Zhang, G., & Xu, Z. (2020) · Frontiers in Physiology · doi:10.3389/fphys.2020.539288 · Cited by 9
“, 2014), and ANGPTL4 (Dewey et al., 2016) inactivating mutants have been reported to decreased CAD susceptibility.”
BackgroundFerence, B. A. (2019) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1163 · Cited by 8
Balling, M., Afzal, S., Varbo, A., Nordestgaard, B. G., & Langsted, A. (2024) · Clinical Chemistry · doi:10.1093/clinchem/hvae217 · Cited by 13
Gagnon, É., Gill, D., Chabot, D., Cronjé, H. T., Yuan, S., Brennan, S., Thériault, S., Burgess, S., Arsenault, B. J., & Dib, M. (2025) · Circulation Genomic and Precision Medicine · doi:10.1161/circgen.124.004933 · Cited by 10
“We first validated the GRS computed using selected genetic instruments for each drug target.”
Genetics of remnant cholesterol
Wulff, A. B., & Nordestgaard, B. G. (2025) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000991 · Cited by 8
Genetics for the Identification of Lipid Targets Beyond PCSK9
Wang, L. R., & Hegele, R. A. (2016) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2016.11.003 · Cited by 9
“bandwagon to develop agents to inhibit ANGPTL4, it is worth recalling that early animal studies with a monoclonal antibody to ANGPTL4 were associated with development of intestinal lipomatosis and granulomatosis (64), which were also observed more recently when mice and monkeys were treated with a similar antibody (63…”
Characterization of sexual dimorphism in ANGPTL4 levels and function
Deng, M., & Kersten, S. (2024) · Journal of Lipid Research · doi:10.1016/j.jlr.2024.100526 · Cited by 8
“Whole-body inactivation via monoclonal antibodies causes a more pronounced lowering of plasma TG yet has been shown to trigger lymphadenopathy in female monkeys (34).”
BackgroundAnother Round of “Clue” to Uncover the Mystery of Complex Traits
Verma, S. S., & Ritchie, M. D. (2018) · Genes · doi:10.3390/genes9020061 · Cited by 10
Self-citationAssociation of a genetic variant in the angiopoietin-like protein 4 gene with metabolic syndrome
kharazmi-Khorassani, S., Khorassani, J. K., Rastgar‐Moghadam, A., Samadi, S., Ghazizadeh, H., Tayefi, M., Ferns, G. A., Ghayour‐Mobarhan, M., Avan, A., & Esmaily, H. (2019) · BMC Medical Genetics · doi:10.1186/s12881-019-0825-8 · Cited by 9
Janssen, L. G. M., Jauhiainen, M., Olkkonen, V. M., Haridas, P. A. N., Nahon, K. J., Rensen, P. C. N., & Boon, M. R. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8081214 · Cited by 9
Hini, S. H. E., Mahmoud, Y. Z., Saedii, A. A., Mahmoud, S. S., Amin, M. A., Mahmoud, S. R., & Matta, R. A. (2021) · Endocrine Connections · doi:10.1530/ec-21-0398 · Cited by 8
Approach to patients with hypertriglyceridemia
Chait, A., & Feingold, K. R. (2022) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2022.101659 · Cited by 11
Do we need new lipid-lowering agents in the era of PCSK9 inhibitors? Recent advances
Atar, D., Langslet, G., & Tonstad, S. (2022) · Kardiologia Polska · doi:10.33963/kp.a2022.0117 · Cited by 12
Murdock, D. R., Guo, D., DePaolo, J. S., Schwarze, U., Duan, X., Cecchi, A. C., Marin, I. C., Tang, Y., Chong, J. X., Bamshad, M. J., et al. (2025) · npj Genomic Medicine · doi:10.1038/s41525-025-00472-w · Cited by 7
“PMBB ES data was processed as previously reported by Regeneron Genomics Center (RGC) 34 .”
Young, E. P., & Stitziel, N. O. (2018) · Annual Review of Medicine · doi:10.1146/annurev-med-041717-085853 · Cited by 7
Protective lipid-lowering variants in healthy older individuals without coronary heart disease
Lacaze, P. A., Riaz, M., Sebra, R., Hooper, A. J., Pang, J., Tiller, J. M., Polekhina, G., Tonkin, A. M., Reid, C. M., Zoungas, S., et al. (2021) · Open Heart · doi:10.1136/openhrt-2021-001710 · Cited by 10
Potential of Phage Display Antibody Technology for Cardiovascular Disease Immunotherapy
Yeoh, S. G., Sum, J.-S., Lai, J. Y., Isa, W. Y. H. W., & Lim, T. S. (2021) · Journal of Cardiovascular Translational Research · doi:10.1007/s12265-021-10169-x · Cited by 8
ANGPTL4 is a potential driver of HCV-induced peripheral insulin resistance
Gomes, D. B. R., Sobolewski, C., Conzelmann, S., Schaer, T., Lefai, É., Alfaiate, D., Tseligka, E. D., Goossens, N., Tapparel, C., Negro, F., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-33728-5 · Cited by 8
“ANGPTL4 is a secreted glycoprotein that belongs to a superfamily of ANGPTLs, and has been implicated in a variety of diseases and biological processes, including cardiovascular disease 51,52 , obesity 53 , diabetes 54,55 , angiogenesis and hypoxia 56,57 .”
BackgroundGenetics-based risk scores for prediction of premature coronary artery disease
Gupta, R. (2023) · Indian Heart Journal · doi:10.1016/j.ihj.2023.08.003 · Cited by 7
Hallén, J., & Sreeharan, N. (2018) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvy029 · Cited by 7
Liabotis, A., Ardidie‐Robouant, C., Mailly, P., Besbes, S., Gutierrez, C., Atlas, Y., Muller, L., Germain, S., & Monnot, C. (2022) · Biomedicines · doi:10.3390/biomedicines10020206 · Cited by 7
“Whereas it is clearly involved in regulating lipid metabolism [36,37], its role in vascular biology has been a matter of debate for long.”
BackgroundPolymorphisms in ANGPTL4 link triglycerides with CAD
Lim, G. B. (2016) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2016.46 · Cited by 7
Fang, Z., Liu, C., Cheng, Y., Ji, Y., & Liu, C. (2025) · Life Sciences · doi:10.1016/j.lfs.2025.123377 · Cited by 6
Qi, Y., Jiang, H., Lun, Y., Gang, Q., Shen, S., Zhang, H., Liu, M., Wang, Y., & Zhang, J. (2025) · Journal of the American Heart Association · doi:10.1161/jaha.124.037802 · Cited by 7
“89 90–92 Moreover, elevated ANGPTL4 expression has been positively correlated with the progression of larger AAAs and an increased risk of rupture.”
Peng, Y., Hu, D., Luo, Q., & Peng, D. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.863687 · Cited by 6
“(25) have further clarified that ANGPTL4 plays a role in plasma triglyceride and very low-density lipoprotein (VLDL) metabolism by inhibiting the LPL activity.”
BackgroundWang, C., Liu, K., Tsai, M., Ho, M.-Y., Yeh, J., Hsieh, C., Wen, M., & Yeh, T. (2020) · Obesity Research & Clinical Practice · doi:10.1016/j.orcp.2020.05.002 · Cited by 6
Khan, M. S., Ishaq, M., Ayub, M. T., Rehman, A. U., Hayes, J. J., Mortada, M. E., & Biederman, R. W. (2021) · Journal of Lipids · doi:10.1155/2021/6696915 · Cited by 5
Should We Use Genetic Scores in the Determination of Treatment Strategies to Control Dyslipidemias?
Lechner, K., Kessler, T., & Schunkert, H. (2020) · Current Cardiology Reports · doi:10.1007/s11886-020-01408-9 · Cited by 6
Surma, S., Romańczyk, M., & Filipiak, K. J. (2021) · Folia Cardiologica · doi:10.5603/fc.2021.0005 · Cited by 6
“It was shown that inactivation of the ANGPTL4 gene was most commonly caused by a heterozygous E40K mutation and resulted in a reduction in plasma total cholesterol, LDL, and triglyceride levels along with an increase in plasma HDL level [12].”
BackgroundInfluentialCabodevilla, A. G., Izquierdo, M. C., Basu, D., Younis, W., Tirumalasetty, M. B., Miao, Q. R., Nasias, D., Kanter, J. E., Ho, T. W. W., Gjini, J., et al. (2026) · Nature Communications · doi:10.1038/s41467-025-68193-3 · Cited by 6
“Othergenes that regulate TG metabolism such as the LpL inhibitors angiopoietin-like protein 3 and 4 (ANGPTL3, ANGPTL4) 57,58 , apolipoprotein C-3 (APOC3) and apolipoprotein A-5 (APOA5) are also linked to the risk of CVD 59,60 .”
Björnson, E., Packard, C. J., & Borén, J. (2026) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2026.109010 · Cited by 6
New and Emerging Therapeutic Targets for ApoB-Containing Particles Lowering
Gaudet, D., Larouche, M., Raal, F. J., & Catapano, A. L. (2026) · Circulation Research · doi:10.1161/circresaha.126.327270 · Cited by 5
İspir, E., Saruhan, E., Topçu, D. İ., Varol, B., Akbaba, E., & Ercan, T. Ç. (2024) · Placenta · doi:10.1016/j.placenta.2024.12.007 · Cited by 9
Li, Y., Zhang, Y., Cao, M., Yuan, T., & Ou, S. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1475198 · Cited by 6
Maidman, S. D., & Rosenson, R. S. (2025) · BioDrugs · doi:10.1007/s40259-025-00731-3 · Cited by 8
“However, a monoclonal antibody targeting ANGPTL4 resulted in the development of abdominal and mesenteric lymphadenopathy in mice and monkeys [86].”
InfluentialYarmolinsky, J. W., Lee, M. A., Lau, E., Moratalla-Navarro, F., Vincent, E. E., Li‐Gao, R., Rensen, P. C. N., van Dijk, K. W., Tsilidis, K. K., Sangphukieo, A., et al. (2025) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djaf137 · Cited by 5
“63 In addition, human genetic inactivation of ANGPTL4 has been shown to improve glucose homeostasis and reduce type 2 diabetes risk.”
Beyond Statins: Who and When to Prescribe?
Ganda, O. P. (2018) · Current Diabetes Reports · doi:10.1007/s11892-018-1087-0 · Cited by 6
Recent updates in dyslipidemia management: perspectives in stroke-specific situation
Seo, W., Hosseini, M. B., Bang, O. Y., & Liebeskind, D. S. (2020) · Precision and Future Medicine · doi:10.23838/pfm.2020.00009 · Cited by 5
“Angiopoietin-like gene (ANGPTL) is another focused target for dyslipidemia management [76-78].”
BackgroundDeep Apolipoprotein Proteomics to Uncover Mechanisms of Coronary Disease Risk ∗
Rader, D. J., Bajaj, A., & Khetarpal, S. A. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.11.066 · Cited by 5
“Coding variation in ANGPTL4, LPL, and SVEP1 and the risk of coronary disease.”
BackgroundRemnant Lipoproteins as a Target for Atherosclerosis Risk Reduction
Levin, M. G. (2021) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.121.316341 · Cited by 6
Molecular Genetics of Coronary Artery Disease
Ozaki, K. (2017) · Wiley eBooks · doi:10.1002/9780470015902.a0027329 · Cited by 5
Alam, U., Mathai, S. V., Filtz, A., Kuno, T., Badimon, J. J., Sniderman, A. D., Virani, S. S., Toth, P. P., Shapiro, M. D., Lavie, C. J., et al. (2026) · Current Cardiology Reports · doi:10.1007/s11886-025-02337-1 · Cited by 4
“Genetic studies have identified individuals with loss-of-function variants in ANGPTL3, who exhibit lifelong reductions in TGs, LDL-C, and HDL-C, and a lower risk of CAD—a finding that has catalyzed therapeutic efforts targeting this protein [26 ].”
Andersson, D. P., Littmann, K., Kindborg, G., Eklund, D., Sejersen, K., Yan, J., Hogling, D. E., Parini, P., & Brinck, J. W. (2024) · European Heart Journal Open · doi:10.1093/ehjopen/oeae010 · Cited by 4
Polygenic Scoring for Detection of Ascending Thoracic Aortic Dilation
DePaolo, J. S., Biagetti, G. M., Judy, R., Wang, G. J., Kelly, J. J., Iyengar, A., Goel, N. J., Desai, N. D., Szeto, W. Y., Bavaria, J. E., et al. (2024) · Circulation Genomic and Precision Medicine · doi:10.1161/circgen.123.004512 · Cited by 5
Dekkar, S., Mahloul, K., Falco, A., Konate, K., Pisteur, R., Maurel, S., Maïmoun, L., Chauvet, N., Boisguérin, P., Nocca, D., et al. (2025) · Journal of Biomedical Science · doi:10.1186/s12929-025-01163-5 · Cited by 5
Asiedu, E. B., Kumar, A., Choi, A., Luciano, D. O., Lo, K., sharma, D., Maa, T., Rassool, F. V., Sodhi, A., & Montaner, S. (2026) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2510265123 · Cited by 7
“These findings also have potential implications for other ANGPTL4 - overexpressing tumors. circulating high - density lipoprotein (HDL) cholesterol levels (15).”
It takes a genome to understand a village: Population scale precision medicine
Butte, A. J. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1615329113 · Cited by 4
Ahn, J. H., Kim, M. C., Ahn, Y., Cho, D. I., Lim, Y., Hyun, D. Y., Lee, S. H., Cho, K. H., Cho, M., Kim, Y. S., et al. (2023) · International Journal of Cardiology · doi:10.1016/j.ijcard.2023.131164 · Cited by 4
DNA and RNA Molecules as a Foundation of Therapy Strategies for Treatment of Cardiovascular Diseases
Rakicevic, L. B. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15082141 · Cited by 4
“In terms of hyperlipidaemia, the gene of interest is ANGPTL4 (Angiopoietin Like 4) [35,36], while the variations of APOC3 (Apolipoprotein C3) are important for hypertriglyceridemia [37].”
BackgroundCorrelation between the serum FABP4, ANGPTL3, and ANGPTL4 levels and coronary artery disease
Zhao, Z., Fu, Y., Lian, H., Liu, Y., Liu, J., Sun, L., & Zhang, Y. (2024) · Clinical Cardiology · doi:10.1002/clc.24246 · Cited by 5
“26,36 However, ANGPTL4 also has the effect of inhibiting inflammation.”
BackgroundResultTo absorb fat — supersize my lipid droplets
Goldberg, I. J., & Hussain, M. M. (2018) · Journal of Clinical Investigation · doi:10.1172/jci125318 · Cited by 4
“TAG-rich lipoproteins in physiology and pathology Why is this important for normal physiology and pathology? TAG-rich lipoproteins have again generated greater interest for their relationship to atherosclerotic cardiovascular disease (CVD), as GWAS studies have implicated genes associated with defective TAG lipolysis…”
BackgroundMircea, A. A. (2023) · Discoveries · doi:10.15190/d.2023.2 · Cited by 4
Investigational drugs in development for hypertriglyceridemia: a coming-of-age story
Rhainds, D., Brodeur, M. R., & Tardif, J. (2019) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2019.1696772 · Cited by 4
“It does not inactivate LPL like ANGPTL4, which favors dissociation of active LPL (dimers) into monomers [100].”
BackgroundInfluentialAlternative Natural Management of Dyslipidemia
Al-Kushi, A. G. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.82430 · Cited by 8
Novel Adipose Tissue Targets to Prevent and Treat Atherosclerosis
Scheja, L., & Heeren, J. (2020) · Handbook of experimental pharmacology · doi:10.1007/164_2020_363 · Cited by 6
Pedro‐Botet, J., Ascaso, J. F., Blasco, M., Brea, Á., Díaz, Á., Hernández‐Mijares, A., Pintó, X., & Millán, J. (2020) · Clínica e Investigación en Arteriosclerosis (English Edition) · doi:10.1016/j.artere.2019.12.001 · Cited by 7
Mekke, J. M., Verwer, M. C., Stroes, E. S. G., Kroon, J., Timmers, L., Pasterkamp, G., de Borst, G. J., van der Laan, S. W., & de Kleijn, D. P. V. (2023) · European Journal of Vascular and Endovascular Surgery · doi:10.1016/j.ejvs.2023.01.035 · Cited by 4
Association of Coronary Protective Factors Among Patients With Acute Coronary Syndromes
Fedačko, J., Singh, R. B., Niaz, M. A., Bhardwaj, K., Verma, N., Gupta, A. K., Singh, V. K., Hristová, K., Saboo, B., Mahashwari, A., et al. (2017) · Journal of Cardiology and Therapy · doi:10.17554/j.issn.2309-6861.2017.04.133 · Cited by 4
The Genetics of Dyslipidemia — When Less Is More
Kersten, S. (2016) · New England Journal of Medicine · doi:10.1056/nejme1601117 · Cited by 5
Li, W., Wang, Y., Huang, R., Feng, L., Xu, G.-X., Wang, W., & Xue, S. (2024) · BMC Cardiovascular Disorders · doi:10.1186/s12872-024-03759-5 · Cited by 3
“These results are consistent with those of previous studies [13].”
BackgroundResultInfluentialDePaolo, J. S., Guo, D., Murdock, D. R., Cecchi, A. C., LeMaire, S. A., Shen, H. Y., Estrera, A. L., Safi, H. J., Coselli, J. S., Smith, J. K., et al. (2026) · Genetics in Medicine · doi:10.1016/j.gim.2026.102571 · Cited by 3
Li, Y., Zhou, X., Wen, Y., Huang, Q., Yang, X., Mukherjee, R., Sutton, R., Liu, T., Cai, W., & Huang, W. (2026) · Biomedicines · doi:10.3390/biomedicines14071574 · Cited by 3
“However, systemic ANGPTL4 blockades have raised safety concerns, including lymphatic lipid accumulation and inflammation in animal models, although newer antibody-based approaches suggest that safer inhibition may be feasible [157,158].”
Yen, I., Lin, S., Lin, M., Lee, C., Kuo, C., Chen, S., Tai, Y., Kuo, C., Kuo, H., Lin, H., et al. (2024) · Clinica Chimica Acta · doi:10.1016/j.cca.2024.117775 · Cited by 4
DePaolo, J., Bornstein, M. R., Judy, R., Abramowitz, S. A., Verma, S. S., Levin, M. G., Biobank, P. M., Arany, Z. P., & Damrauer, S. M. (2025) · PLoS Genetics · doi:10.1371/journal.pgen.1011727 · Cited by 3
“Whole exome sequencing was performed as previously described by Regeneron Genomics Center [26], Individual patient DNA samples were processed and sequenced on the Illumina NovaSeq 6000 (Albany, NY, USA).”
Zambon, A., Gentile, L., Galimberti, F., Manzato, E., Giaccari, A., Sesti, G., Belfiore, A., Norata, G. D., Temporelli, P. L., Frulloni, L., et al. (2025) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2025.104214 · Cited by 3
Inhibition of ANGPTL3 as a Target for Treating Dyslipidemias
Watts, G. F., Chan, D. C., & Raal, F. J. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-88286-6.00027-3 · Cited by 3
Rong, Y., Wu, Q., Tang, J., Liu, Z., Lv, Q., Ye, X., Dong, Y. J., Zhang, Y., Li, G., & Wang, S. (2022) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2022/4463108 · Cited by 3
“/e human Angptl4 E40K mutation can deactivate Angptl4, thereby reducing triglycerides, increasing high-density lipoprotein cholesterol, and reducing dyslipidemia and arteriosclerosis [37], as well as the incidence of cardiovascular disease [38].”
BackgroundPharmacogenomics of Blood Lipid Regulation
Legault, M., Tardif, J., & Dubé, M. (2018) · Pharmacogenomics · doi:10.2217/pgs-2018-0007 · Cited by 4
Nordestgaard, B. G., & Varbo, A. (2020) · Contemporary cardiology · doi:10.1007/978-3-030-56514-5_8 · Cited by 4
Rader, D. J., & Kathiresan, S. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-801812-5.00001-9 · Cited by 5
Lifestyle Approaches to Lowering Triglycerides
Hankinson, S. J., Miller, M. J., & Freeman, A. M. (2021) · Contemporary cardiology · doi:10.1007/978-3-030-78177-4_14 · Cited by 2
Metadata
- Authors
- Dewey, F. E., Gusarova, V., O’Dushlaine, C., Gottesman, O., Trejos, J., Hunt, C., Van Hout, C. V., Habegger, L., Buckler, D., Lai, K.-M. V., Leader, J. B., Murray, M. F., Ritchie, M. D., Kirchner, H. L., Ledbetter, D. H., Penn, J., Lopez, A., Borecki, I. B., Overton, J. D., Reid, J. G., Carey, D. J., Murphy, A. J., Yancopoulos, G. D., Baras, A., Gromada, J., & Shuldiner, A. R.
- Affiliations
- Regeneron (United States) (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2016-03-24
- Volume
- 374
- Issue
- 12
- Pages
- 1123-1133
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC4900689
- OpenAlex
- W2323589075
- Cited by
- 497
- References
- 40
- Citations by year
- 2026: 33 · 2025: 40 · 2024: 38 · 2023: 36 · 2022: 41 · 2021: 63 · 2020: 52 · 2019: 51 · 2018: 53 · 2017: 57 · 2016: 33
- FWCI
- 53.39
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institute of Diabetes and Digestive and Kidney Diseases (P30DK072488)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Keywords
- ANGPTL4, loss-of-function mutations, coronary artery disease, triglycerides, HDL cholesterol, lipoprotein lipase, genetic variants, monoclonal antibody inhibition, serum lipids, genetic association studies
- MeSH terms
- Angiopoietin-Like Protein 4, Aged, Animals, Cholesterol, Coronary Artery Disease, Disease Models, Animal, Female, Heterozygote, Humans, Macaca mulatta, Male, Middle Aged, Mutation, Risk Factors, Triglycerides, Gene Silencing, Angiopoietins, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.